Cytokinetics Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while Virgin Galactic Holdings, Inc. trades at $3.29 (market cap $488.94M). The key difference: Cytokinetics Inc is far larger — about 22× Virgin Galactic Holdings, Inc.'s market cap, and Cytokinetics Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CYTK | SPCE | |
|---|---|---|
Market Cap | $10.78B | $488.94M |
Sector | Technology | Industrials |
52-Week High | $87.26 | $7.52 |
52-Week Low | $34.31 | $2.17 |
Enterprise Value | $10.88B | $588.79M |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →